Jie Mao

Jie Mao

Auto-generated profile, based on publicly available information

Jie Mao

Longgang Central Hospital of Shenzhen

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2026 in Cancers
Verified
Journal Article
Open access
PDF file
JMJie Mao
Jie Mao
JXjinquan xia
jinquan xia
HSHuibin Song
Huibin Song
FZFuhua Zhong
Fuhua Zhong
HFHuiyi Feng
Huiyi Feng
GWGuangsuo Wang
Guangsuo Wang
Background: Tumor invasion is the central barrier to effective immunotherapy in lung adenocarcinoma (LUAD) and glioblastoma. Cell adhesion signaling critically shapes tumor–microenvironment interactions, yet the upstream regulators coordinating these invasive programs at single-cell resolution remain incompletely understood. Methyltransferase Like protein 7B (METTL7B) has recently emerged as a candidate oncogenic regulator, but its lineage-specific functions and the potential downstream effectors are unclear. Methods: We integrated publicly available single-cell RNA sequencing datasets from LUAD and glioblastoma with The Cancer Genome Atlas (TCGA) transcriptomic analyses to resolve METTL7B-associated malignant cell states and microenvironmental interactions. Functional enrichment analyses identified invasion- and focal adhesion pathways linked to METTL7B expression. Gain- and loss-of-function experiments were conducted in LUAD and glioblastoma cell lines to validate downstream cell adhesion effectors. Spatial expression patterns were examined using immunofluorescence, and transwell assays were used to assess migratory and invasive phenotypes. Results: Single-cell analyses revealed that METTL7B was selectively enriched in malignant epithelial cells in LUAD and glioblastoma and defined a transcriptional program characterized by cell adhesion signaling. Integrin Alpha 3 (ITGA3) emerged as a conserved downstream effector of METTL7B, with progressive upregulation from minimally invasive to invasive LUAD and glioblastoma. Functional perturbation confirmed that METTL7B enhances tumor cell migration and invasion through integrin-associated pathways. Conclusions: METTL7B acts as a potential lineage-enriched regulator of invasive tumor states by activating cell adhesion signaling in LUAD and glioblastoma. These findings position METTL7B as a putative prognostic factor for strategies aimed at limiting invasion in lung cancer and glioblastoma.

17 June 2026 in Biomedical Materials
Verified
Journal Article
Closed access
XCXiang Chen
Xiang Chen
HWHuibin Wu
Huibin Wu
XPXinyu Pan
Xinyu Pan
WLWeiqun Li
Weiqun Li
HDHaibing Dai
Haibing Dai
JYJianbo Yu
Jianbo Yu
Cancer remains a major global health burden, with conventional monotherapies often constrained by recurrence, resistance, and systemic toxicity. Natural products derived from plants, animals, microorganisms, and minerals exhibit broad anticancer potential by engaging multiple mechanistic pathways. However, their clinical application is limited by poor solubility, low bioavailability, and chemical instability. Nano-delivery systems (NDS) have emerged as a promising strategy to address these limitations by enhancing pharmacokinetics, stabilizing labile compounds, and enabling co-delivery with conventional drugs, thereby supporting multimodal and synergistic interventions. This review summarizes current applications of natural products in NDS-based cancer therapy, beginning with their classification and mechanistic axes, followed by strategies through which NDS improves pharmacological performance and facilitates integration into combination regimens. Finally, this review highlights both significant progress and challenges, providing a foundation for future advances in translational cancer therapy.